Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Find a Lilly Clinical Trial
68 Enrolling
136 Total Trials
Pinned
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
Pinned
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Migraine
Trial Name
PIONEER-PEDS1
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
Pinned
Conditions: Migraine
Trial Name
REBUILD-1
Drugs: Galcanezumab
Age
6 - 17 years
Phase
III
Pinned
Conditions: Heart Failure
Drugs: LY3540378
Age
≥18 years
Phase
II
Pinned
Conditions: Obesity, Overweight and Cardiovascular Disease
Trial Name
TRIUMPH-3
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Migraine
Trial Name
REBUILD-2
Drugs: Galcanezumab
Age
12 - 17 years
Phase
III
Pinned
Conditions: Alzheimer's disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60 - 85 years
Phase
III
Pinned
Conditions: Obesity, Overweight and Osteoarthritis of the Knee
Trial Name
TRIUMPH-4
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
Pinned
Conditions: Diabetic Peripheral Neuropathy
Drugs: LY3556050
Age
≥18 years
Phase
II
Pinned
Conditions: Obesity
Drugs: Mazdutide
Age
18 - 75 years
Phase
II
Pinned
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18 years
Phase
III
Pinned
Conditions: Rheumatoid Arthritis
Drugs: LY3871801
Age
≥18 years
Phase
II
Conditions: Non-Small Cell Lung Cancer
Trial Name
SUNRAY-01
Drugs: LY3537982, Pemetrexed, Pembrolizumab, Cisplatin, Carboplatin
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18 - 75 years
Phase
II
Conditions: Atherosclerotic cardiovascular disease, Elevated Lp(a)
Drugs: Lepodisiran
Age
≥18 years
Phase
III
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65 - 80 years
Phase
III
Conditions: Solid tumors
Drugs: LY4101174
Age
≥18 years
Phase
I
Conditions: Type 2 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec
Age
18 - 70 years
Phase
I
Conditions: Obesity
Drugs: LY3841136
Age
18 - 65 years
Phase
I
Conditions: Obesity
Drugs: retatrutide
Age
18 - 60 years
Phase
I
Conditions: Breast Cancer
Trial Name
EMBER-4
Drugs: Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Age
≥18 years
Phase
III
Conditions: Overweight, Obesity
Drugs: LY3841136, Tirzepatide
Age
18 - 65 years
Phase
I
Conditions: Lung Cancer, Advanced Solid Tumors
Drugs: LY3537982, Abemaciclib, Pembrolizumab, LY3295668, Cetuximab
Age
≥18 years
Phase
I
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-3
Drugs: Orforglipron, Semaglutide
Age
≥18 years
Phase
III
Conditions: Obesity, Overweight
Drugs: LY3841136
Age
18 - 75 years
Phase
II
Conditions: Breast Cancer
Trial Name
EMBER-3
Drugs: LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib
Age
≥18 years
Phase
III
Conditions: Ulcerative Colitis
Trial Name
LUCENT 3
Drugs: Mirikizumab
Age
18 - 80 years
Phase
III
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21 years
Phase
II
Conditions: Crohn's Disease
Trial Name
SHINE-On
Drugs: Mirikizumab
Age
2 - 19 years
Phase
III
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1 year - 18 years
Phase
III
Conditions: Migraine
Trial Name
PIONEER-PEDS2
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
Conditions: COVID-19
Trial Name
COV-BARRIER-PEDS
Drugs: Baricitinib, LY3009104
Age
2 - 18 years
Phase
III
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-2
Drugs: retatrutide, semaglutide
Age
≥18 years
Phase
III
Conditions: Crohn's Disease
Trial Name
VIVID-2
Drugs: Mirikizumab
Age
≥18 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1 year - 39 years
Phase
II
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2 - 17 years
Phase
III
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18 years
Phase
II
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
Conditions: Hidradenitis Suppurativa
Drugs: Eltrekibart
Age
18 - 75 years
Phase
II
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
Conditions: Multiple sclerosis
Drugs: LY3541860
Age
18 - 55 years
Phase
II
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2 - 17 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Drugs: Ucenprubart
Age
18 - 70 years
Phase
II
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-5
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-3
Drugs: retatrutide
Age
≥18 years
Phase
III
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRANCH
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
Conditions: Obesity, Overweight, Chronic kidney disease
Drugs: retatrutide
Age
≥18 years
Phase
II
Conditions: Bladder Cancer, Advanced Solid Tumors
Drugs: LOX-24350 / LOXO-435, Pembrolizumab
Age
≥18 years
Phase
I
Conditions: Non-Small Cell Lung Cancer
Trial Name
LIBRETTO-432
Drugs: Selpercatinib
Age
≥18 years
Phase
III
Conditions: Breast Cancer, Advanced Solid Tumors
Trial Name
PIKASSO-01
Drugs: LOXO-783
Age
≥18 years
Phase
I
Conditions: Type 2 diabetes
Trial Name
ACHIEVE-2
Drugs: dapagliflozin, orforglipron
Age
≥18 years
Phase
III
Conditions: Non-Alcoholic Fatty Liver Disease
Drugs: LY3849891
Age
18 - 70 years
Phase
I
Conditions: Ulcerative Colitis
Trial Name
LUCENT-URGE
Drugs: Mirikizumab
Age
≥18 years
Phase
III
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1 year - 17 years
Phase
III
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6 - 17 years
Phase
III
Conditions: Plaque Psoriasis
Drugs: LY3972406
Age
18 - 75 years
Phase
II
Conditions: Gaucher Disease, Type 1
Trial Name
PROCEED
Drugs: LY3884961, an investigational gene therapy
Age
18 - 65 years
Phase
II
Conditions: Hepatic Impairment, Healthy Participants
Drugs: Orforglipron
Age
18 - 80 years
Phase
I
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-322
Drugs: Pirtobrutinib, Rituximab, Venetoclax
Age
≥18 years
Phase
III
Conditions: Mantle Cell Lymphoma
Trial Name
BRUIN-MCL-321
Drugs: Acalabrutinib, Ibrutinib, Pirtobrutinib, Zanubrutinib
Age
≥18 years
Phase
III
Conditions: Chronic Lymphocytic Leukemia, B-cell Leukemias, Small Lymphocytic Lymphomas
Trial Name
BRUIN-CLL-314
Drugs: Pirtobrutinib, Ibrutinib
Age
≥18 years
Phase
III
8 Not Yet Enrolling
136 Total Trials
Conditions: Obesity
Drugs: Tirzepatide (LY3298176), Mibavademab
Age
≥18 years
Phase
II
Conditions: Type 2 diabetes
Drugs: LY3209590
Age
10 - 17 years
Phase
I
Conditions: Atopic Dermatitis (Eczema)
Drugs: lebrikizumab, topical corticosteroid
Age
≥12 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
TRANSCEND-T2D-1
Drugs: retatrutide
Age
≥18 years
Phase
III
Conditions: Alzheimer's Disease
Drugs: LY3954068, Flortaucipir F18
Age
50 - 85 years
Phase
I
Conditions: Perennial Allergic Rhinitis (PAR)
Trial Name
PREPARED-1
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
Conditions: Type 1 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec, insulin lispro
Age
18 - 64 years
Phase
I
60
Completed Enrollment
136 Total Trials
Conditions: Obesity, Overweight, Type 2 Diabetes
Trial Name
ATTAIN-2
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Obesity
Trial Name
ATTAIN-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
SURPASS-CVOT
Drugs: Tirzepatide, Dulaglutide
Age
≥40 years
Phase
III
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-321
Drugs: Bendamustine, Idelalisib, LOXO-305, Rituximab
Age
≥18 years
Phase
III
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA1
Drugs: Baricitinib
Age
18 - 70 years
Phase
III
Conditions: Ulcerative Colitis
Trial Name
LUCENT 1
Drugs: Mirikizumab, Placebo
Age
18 - 80 years
Phase
III
Conditions: Aicardi Goutieres Syndrome (AGS)
Drugs: Baricitinib
Age
≥6 months
Phase
III
Conditions: Heart Failure
Drugs: LY3461767
Age
18 - 80 years
Phase
I
Conditions: Atopic Dermatitis (Eczema)
Trial Name
BREEZE-AD-PEDS
Drugs: Baricitinib, Placebo
Age
2 - 17 years
Phase
III
Conditions: Advanced Solid Tumor
Trial Name
PACT
Drugs: Ramucirumab, Abemaciclib, Merestinib, LY3300054
Age
≥18 years
Phase
I
Conditions: Breast Cancer
Trial Name
monarchE
Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Age
≥18 years
Phase
III
Conditions: Obesity
Trial Name
SURMOUNT-MMO
Drugs: Tirzepatide
Age
≥40 years
Phase
III
Conditions: Obesity
Trial Name
ATTAIN-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
Conditions: Prostate Cancer
Drugs: Abemaciclib, Darolutamide, LHRH agonist/antagonist
Age
≥18 years
Phase
I
Conditions: Prostate Cancer
Trial Name
CYCLONE 2
Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Age
≥18 years
Phase
III
Conditions: Desmoplastic Small Round Cell Tumor
Trial Name
CAMPFIRE
Drugs: Cyclophosphamide, Ramucirumab, Vinorelbine
Age
12 months - 29 years
Phase
II
Conditions: Uveitis
Drugs: Baricitinib, Adalimumab
Age
2 - 17 years
Phase
III
Conditions: Alzheimer's Disease
Trial Name
PROSPECT-ALZ
Drugs: LY3372689
Age
60 - 85 years
Phase
II
Conditions: Prostate Cancer
Trial Name
CYCLONE 3
Drugs: Abemaciclib, Abiraterone, LY2835219, Prednisone, Prednisolone
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
QWINT-3
Drugs: LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
Completed Enrollment
Conditions: High Cholesterol and/or High Triglycerides
Trial Name
PROLONG-ANG3
Drugs: LY3561774
Age
≥18 years
Phase
II
Conditions: Non-Small Cell Lung Cancer
Trial Name
JUNIPER
Drugs: Abemaciclib, Erlotinib
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
SURPASS-SWITCH
Drugs: Dulaglutide, Tirzepatide
Age
≥18 years
Phase
IV
Completed Enrollment
Conditions: Obesity
Trial Name
SURMOUNT-1
Drugs: Tirzepatide, Placebo
Age
≥18 years
Phase
III
Conditions: Obesity, Overweight
Drugs: Tirzepatide (LY3298176)
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
QWINT-1
Drugs: LY3209590, Insulin Glargine, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
Conditions: Soft Tissue Sarcoma
Trial Name
ANNOUNCE
Drugs: Olaratumab/Placebo, Doxorubicin
Age
≥18 years
Phase
III
Completed Enrollment
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRIDGE
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
Conditions: Breast Cancer
Trial Name
postMONARCH
Drugs: Abemaciclib, Fulvestrant
Age
≥18 years
Phase
III
Conditions: Breast Cancer
Trial Name
Next MONARCH 1
Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Age
≥18 years
Phase
II
Conditions: Type 2 Diabetes
Trial Name
SURPASS-EARLY
Drugs: Antihyperglycemic medication, Tirzepatide
Age
≥18 years
Phase
IV
Completed Enrollment
Conditions: Breast Cancer
Trial Name
MONARCH plus
Drugs: Abemaciclib, Anastrozole, Letrozole, Fulvestrant
Age
≥18 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADapt
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
QWINT-2
Drugs: LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
Conditions: Type 1 Diabetes
Trial Name
QWINT-5
Drugs: Insulin degludec, Insulin Efsitora Alfa, LY3209590
Age
≥18 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
SURPASS-PEDS
Drugs: Tirzepatide
Age
10 - 18 years
Phase
III
Completed Enrollment
Conditions: Lipoprotein Disorder
Trial Name
ALPACA
Drugs: LY3819469
Age
≥40 years
Phase
II
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-313
Drugs: Bendamustine, Pirtobrutinib, Rituximab
Age
≥18 years
Phase
III
Conditions: Lung Cancer, Thyroid Cancer and other Solid Tumors
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12 years
Phase
I
Conditions: Breast Cancer, Endometrial Cancer
Trial Name
EMBER
Drugs: LY3484356, Abemaciclib
Age
≥18 years
Phase
I
Conditions: Neuroblastoma
Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Age
2 - 21 years
Phase
I
Conditions: Breast Cancer
Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane
Age
≥18 years
Phase
I
Conditions: Breast Cancer, Non-Small Cell Lung Cancer
Drugs: Abemaciclib, Pembrolizumab
Age
≥18 years
Phase
I
Conditions: Alzheimer's Disease
Drugs: LY3372993
Age
18 - 85 years
Phase
I
Conditions: Non-small Cell Lung Cancer
Trial Name
LIBRETTO-431
Drugs: Carboplatin, Cisplatin, Pembrolizumab, Pemetrexed, Selpercatinib
Age
≥18 years
Phase
III
Conditions: Arthritis
Drugs: Ixekizumab, Adalimumab
Age
2 - 17 years
Phase
III
Conditions: Ulcerative Colitis
Trial Name
LUCENT 2
Drugs: Mirikizumab, Placebo
Age
18 - 80 years
Phase
III
Conditions: Non-Small Cell Lung Cancer
Trial Name
RELAY
Drugs: Ramucirumab, Erlotinib
Age
≥18 years
Phase
III
Conditions: Breast Cancer
Trial Name
eMonarcHER
Drugs: Abemaciclib Plus Hormone Therapy
Age
≥18 years
Phase
III
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 2
Drugs: Donanemab
Age
60 - 85 years
Phase
III
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3200882
Age
≥18 years
Phase
I
Conditions: Advanced Solid Tumor
Drugs: Ramucirumab, cisplatin, gemcitabine, Merestinib
Age
≥18 years
Phase
II
Conditions: Rheumatoid Arthritis
Trial Name
RESOLUTION-1
Drugs: Peresolimab
Age
≥18 years
Phase
II
Conditions: Obesity, Heart Failure
Trial Name
SUMMIT
Drugs: Tirzepatide
Age
≥40 years
Phase
III
Conditions: Overweight, Obesity
Trial Name
SURMOUNT-5
Drugs: Tirzepatide, Semaglutide
Age
≥18 years
Phase
III
Conditions: Medullary Thyroid Cancer
Trial Name
LIBRETTO-531
Drugs: Selpercatinib, Cabozantinib, Vandetanib
Age
≥12 years
Phase
III
Conditions: Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
Trial Name
I9Y-OX-JDHB
Drugs: LY3410738
Age
≥18 years
Phase
I
Conditions: Advanced Solid Tumor
Drugs: LY3410738
Age
≥18 years
Phase
I
Conditions: Alopecia Areata (Hair Loss)
Trial Name
BRAVE-AA2
Drugs: Baricitinib, Placebo
Age
18 - 70 years
Phase
III
Completed Enrollment
Conditions: Blood Cancers
Drugs: LOXO-338 / LY3847429, Pirtobruitinib
Age
≥18 years
Phase
I